Shire plc Press Releases

SHPG 
$246.5
*  
4.74
1.89%
Get SHPG Alerts
*Delayed - data as of Jul. 31, 2014  -  Find a broker to begin trading SHPG now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen
7/23/2014 7:00:00 AM - PR Newswire

SHIRE SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Believe the Buyout of Shire by AbbVie May be Unfair to Shareholders
7/18/2014 12:46:00 PM - Business Wire

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
7/18/2014 6:14:00 AM - PR Newswire

Shire Reports Top-Line Results From Two Head-to-Head Studies Comparing Vyvanse® (lisdexamfetamine dimesylate), CII, With Concerta® (methylphenidate HCl), CII, in Adolescents with ADHD
7/17/2014 1:30:00 PM - PR Newswire

Shire plc: Update re: AbbVie Proposal
7/14/2014 2:34:00 AM - PR Newswire

Shire plc - Statement re: Media Speculation
7/11/2014 2:00:00 PM - PR Newswire

Shire plc - Statement re: AbbVie Announcement
7/8/2014 9:44:00 AM - PR Newswire

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
7/8/2014 7:50:00 AM - PR Newswire

Shire Receives US$248 Million Cash Refund From the Canadian Revenue Authorities, Expects a Further US$162 Million in Late 2014
6/30/2014 2:00:00 AM - PR Newswire

Shire Comments on AbbVie's Unchanged Proposal
6/25/2014 11:47:00 AM - PR Newswire

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
6/25/2014 8:45:00 AM - PR Newswire

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
6/25/2014 7:29:00 AM - PR Newswire

Vyvanse® Patents Found to Be Infringed and Valid by U.S. District Court
6/25/2014 2:44:00 AM - PR Newswire

Shire plc: the Path to US$10 Billion in Product Sales by 2020
6/23/2014 7:33:00 AM - PR Newswire

Shire to Host Investor Call
6/23/2014 2:00:00 AM - PR Newswire

Shire Update Call for Investors
6/20/2014 1:39:00 PM - PR Newswire

Shire Confirms Rejection of AbbVie Proposal
6/20/2014 4:22:00 AM - PR Newswire

Shire Agrees to FDA Request to Conduct Clinical Trials Investigating the Potential Use of Vyvanse® (lisdexamfetamine dimesylate) in Preschool-Age Children with ADHD
6/12/2014 9:00:00 AM - PR Newswire

Shire to Participate at the Goldman Sachs 35th Annual Global Healthcare Conference
6/10/2014 9:30:00 AM - PR Newswire

SHAREHOLDER ALERT: Pomerantz LLP Investigates Claims That the Merger May Not Be in the Best Interest of Investors of NPS Pharmaceuticals, Inc. - NPSP
6/2/2014 12:34:00 PM - PR Newswire

Shire to Present at the Jefferies 2014 Global Healthcare Conference
6/2/2014 7:00:00 AM - PR Newswire

Shire Plans to Submit a New Drug Application to FDA for Lifitegrast for Dry Eye Disease in Adults
5/19/2014 2:00:00 AM - PR Newswire

Shire Plans to Submit a New Drug Application to FDA for Lifitegrast for Dry Eye Disease in Adults
5/16/2014 11:43:00 AM - PR Newswire

Shire Adds to Rare Disease Portfolio with Acquisition of Lumena Pharmaceuticals, Bringing Late Stage Compounds for Rare GI/Hepatic Conditions
5/12/2014 7:00:00 AM - PR Newswire